Performance of an Automated Insulin Delivery System in People Living With Type 2 Diabetes and Insulin Resistance: First Real-World Evidence in 26,427 Users
Authors' conclusion
The use of this AID is associated with effective therapy outcomes, as indicated by over 70% TIR, and appears to be safe, as demonstrated by a low TBR in a large cohort of real-life users with self-reported T2D and high or low TDD.
Study context
- Population
- MiniMed 780G automated insulin delivery (AID) users with T2D phenotypes, data uploaded to CareLink Personal (January 2020 to April 2024)
- Participants
- 18,466 / 10,795 / 2,834 / 7,961
- Exposure
- Cohorts of MM780G AID users with T2D phenotypes by insulin requirement
- Cohort An = 18,466
- Cohort Bn = 10,795
- Cohort Cn = 2,834
- Cohort Dn = 7,961
- Outcome
- TIR
- Follow-up
- Post-AID
Main finding
As reported in the abstract
Observational data: associations, not effects.
Further findings
- Time in range (TIR) in cohort C using recommended optimal settings (GT 100 mg/dL, AIT 2 hours)
- 78.7 · ± 10.8 · %
TIR post-AID vs pre-AID
- All cohorts increased ≥10% post-AID compared with pre-AID
Safety
- Mean time below range (TBR) <70 mg/dL in all cohorts
- ≤1%
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Performance of an Automated Insulin Delivery System in People Living With Type 2 Diabetes and Insulin Resistance: First Real-World Evidence in 26,427 Users. J Diabetes Sci Technol. Published 12 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →